CR9848A - Combinacion de rosiglitazona y donepezil para mejorar la funcion cognitiva - Google Patents
Combinacion de rosiglitazona y donepezil para mejorar la funcion cognitivaInfo
- Publication number
- CR9848A CR9848A CR9848A CR9848A CR9848A CR 9848 A CR9848 A CR 9848A CR 9848 A CR9848 A CR 9848A CR 9848 A CR9848 A CR 9848A CR 9848 A CR9848 A CR 9848A
- Authority
- CR
- Costa Rica
- Prior art keywords
- donepezil
- rosiglitazona
- combination
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title abstract 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title abstract 5
- 229960003530 donepezil Drugs 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- 229960004586 rosiglitazone Drugs 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71935305P | 2005-09-22 | 2005-09-22 | |
| US72737705P | 2005-10-17 | 2005-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR9848A true CR9848A (es) | 2008-06-18 |
Family
ID=37876831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR9848A CR9848A (es) | 2005-09-22 | 2008-03-28 | Combinacion de rosiglitazona y donepezil para mejorar la funcion cognitiva |
| CR9849A CR9849A (es) | 2005-09-22 | 2008-03-28 | Agonistas del receptor gamma activado por el proliferador de peroxisomas para la mejora de la funcion cognitiva en pacientes con apolipoproteina e4 negativa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR9849A CR9849A (es) | 2005-09-22 | 2008-03-28 | Agonistas del receptor gamma activado por el proliferador de peroxisomas para la mejora de la funcion cognitiva en pacientes con apolipoproteina e4 negativa |
Country Status (16)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2066355A2 (en) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| WO2009043593A1 (en) * | 2007-10-05 | 2009-04-09 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using memantine and glitazones |
| EP2085120A1 (en) * | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
| KR20160127181A (ko) | 2008-08-12 | 2016-11-02 | 진판델 파마슈티컬스 인코포레이티드 | 질환 위험 인자의 식별 방법 |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| US20100152249A1 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of The Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| NZ597319A (en) * | 2009-06-25 | 2014-06-27 | Alcobra Ltd | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition |
| US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| WO2012053016A1 (en) * | 2010-10-22 | 2012-04-26 | Cadila Healthcare Limited | Sustained release pharmaceutical compositions of donepezil |
| CN107362165A (zh) | 2011-01-10 | 2017-11-21 | 金帆德尔制药股份有限公司 | 用于治疗阿尔茨海默病的方法和药物产品 |
| BR112013017444A2 (pt) * | 2011-01-10 | 2016-09-27 | Zinfandel Pharmaceuticals Inc | método de determinar o risco para o desenvolvimento da doença de alzheimer em um indivíduo, de tratar um indivíduo para a doença de alzheimer e de determinar um risco para desenvolver a doença de alzheimer em um paciente |
| AP2014007645A0 (en) | 2011-10-21 | 2014-05-31 | Takeda Pharmaceutical | Sustained-release preparation |
| CA2853100A1 (en) * | 2011-10-24 | 2013-05-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
| US20160113913A1 (en) * | 2013-04-19 | 2016-04-28 | Takeda Pharmaceutical Company Limited | Controlled-release drug formulation |
| JP6961694B2 (ja) * | 2016-07-26 | 2021-11-05 | オージオ・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | Ｓ−エコールを用いてアルツハイマー病を診断するおよび治療する方法 |
| US20180153859A1 (en) * | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype |
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
| KR102224917B1 (ko) | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2142300C (en) * | 1992-10-13 | 2005-08-23 | Allen D. Roses | Methods for detecting alzheimer's disease |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| ATE476978T1 (de) * | 1998-12-17 | 2010-08-15 | Mindset Biopharmaceuticals Usa | Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns |
| WO2005074917A1 (en) * | 2004-01-30 | 2005-08-18 | Axonyx, Inc. | Methods for treatment of complications of diabetes |
-
2006
- 2006-09-20 EA EA200800879A patent/EA200800879A1/ru unknown
- 2006-09-20 JP JP2008532341A patent/JP2009508960A/ja active Pending
- 2006-09-20 JP JP2008532338A patent/JP2009508959A/ja active Pending
- 2006-09-20 AU AU2006295007A patent/AU2006295007A1/en not_active Abandoned
- 2006-09-20 TW TW095134699A patent/TW200803896A/zh unknown
- 2006-09-20 KR KR1020087009286A patent/KR20080058413A/ko not_active Withdrawn
- 2006-09-20 BR BRPI0616192-8A patent/BRPI0616192A2/pt not_active Application Discontinuation
- 2006-09-20 EP EP06815011A patent/EP1926488A2/en not_active Withdrawn
- 2006-09-20 EP EP06803887A patent/EP1940403A2/en not_active Withdrawn
- 2006-09-20 TW TW095134700A patent/TW200803851A/zh unknown
- 2006-09-20 CA CA002623210A patent/CA2623210A1/en not_active Abandoned
- 2006-09-20 WO PCT/US2006/036597 patent/WO2007038112A2/en not_active Ceased
- 2006-09-20 US US12/067,374 patent/US20080262047A1/en not_active Abandoned
- 2006-09-20 KR KR1020087009295A patent/KR20080056731A/ko not_active Withdrawn
- 2006-09-20 BR BRPI0616100-6A patent/BRPI0616100A2/pt not_active Application Discontinuation
- 2006-09-20 WO PCT/US2006/036603 patent/WO2007038115A2/en not_active Ceased
- 2006-09-20 US US12/067,382 patent/US20080226719A1/en not_active Abandoned
- 2006-09-20 AU AU2006295010A patent/AU2006295010A1/en not_active Abandoned
- 2006-09-20 EA EA200800880A patent/EA200800880A1/ru unknown
- 2006-09-20 CA CA002623204A patent/CA2623204A1/en not_active Abandoned
- 2006-09-21 PE PE2006001143A patent/PE20070976A1/es not_active Application Discontinuation
- 2006-09-21 PE PE2006001145A patent/PE20070618A1/es not_active Application Discontinuation
- 2006-09-25 AR ARP060104148A patent/AR056527A1/es unknown
- 2006-09-25 AR ARP060104149A patent/AR055649A1/es unknown
-
2008
- 2008-03-17 IL IL190217A patent/IL190217A0/en unknown
- 2008-03-17 IL IL190224A patent/IL190224A0/en unknown
- 2008-03-28 CR CR9848A patent/CR9848A/es not_active Application Discontinuation
- 2008-03-28 CR CR9849A patent/CR9849A/es not_active Application Discontinuation
- 2008-04-15 MA MA30850A patent/MA29872B1/fr unknown
- 2008-04-15 MA MA30849A patent/MA29871B1/fr unknown
- 2008-04-16 NO NO20081843A patent/NO20081843L/no not_active Application Discontinuation
- 2008-04-16 NO NO20081847A patent/NO20081847L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CR9849A (es) | 2008-05-21 |
| JP2009508960A (ja) | 2009-03-05 |
| MA29872B1 (fr) | 2008-10-03 |
| PE20070618A1 (es) | 2007-07-04 |
| AR056527A1 (es) | 2007-10-10 |
| US20080262047A1 (en) | 2008-10-23 |
| MA29871B1 (fr) | 2008-10-03 |
| IL190224A0 (en) | 2008-11-03 |
| WO2007038115A2 (en) | 2007-04-05 |
| WO2007038112A3 (en) | 2007-12-06 |
| IL190217A0 (en) | 2008-11-03 |
| CA2623204A1 (en) | 2007-04-05 |
| EA200800879A1 (ru) | 2008-10-30 |
| KR20080056731A (ko) | 2008-06-23 |
| KR20080058413A (ko) | 2008-06-25 |
| TW200803896A (en) | 2008-01-16 |
| BRPI0616192A2 (pt) | 2011-06-14 |
| NO20081843L (no) | 2008-06-16 |
| TW200803851A (en) | 2008-01-16 |
| AR055649A1 (es) | 2007-08-29 |
| AU2006295007A1 (en) | 2007-04-05 |
| EP1926488A2 (en) | 2008-06-04 |
| PE20070976A1 (es) | 2007-12-05 |
| EA200800880A1 (ru) | 2009-02-27 |
| AU2006295010A1 (en) | 2007-04-05 |
| BRPI0616100A2 (pt) | 2011-06-07 |
| WO2007038112A2 (en) | 2007-04-05 |
| NO20081847L (no) | 2008-06-18 |
| EP1940403A2 (en) | 2008-07-09 |
| WO2007038115A3 (en) | 2007-12-13 |
| US20080226719A1 (en) | 2008-09-18 |
| JP2009508959A (ja) | 2009-03-05 |
| CA2623210A1 (en) | 2007-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056527A1 (es) | Composicion farmaceutica para mejorar la funcion cognitiva | |
| AR054139A1 (es) | Formulacion modificada y de liberacion inmediata de esferas de memantina | |
| HN2004000490A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente | |
| PE20070531A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
| MX2020008616A (es) | Rocio de fentanilo sublingual. | |
| BRPI0607017B8 (pt) | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc | |
| CL2007003685A1 (es) | Compuestos derivados de indol con un anillo unido en las posiciones 4 y 5; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion viral. | |
| CL2007003684A1 (es) | Compuestos derivados de indol con un anillo unido en las posiciones 5 y 6; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion viral. | |
| EP1851237A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF BONE DISEASES | |
| ECSP088499A (es) | Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia | |
| CR10355A (es) | Antagonistas de los piridil amida de los canales de calcio de tipo t | |
| CL2008001855A1 (es) | Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa. | |
| CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
| EA200601227A1 (ru) | Применение ротиготина для лечения или предотвращения гибели дофаминергических нейронов | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| CL2007001917A1 (es) | Compuestos derivados de azaindol espirociclicos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del dolor, condiciones de panico, depresion, mal de alzheimer, migrana, entre otras. | |
| CL2011002847A1 (es) | Uso de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida o una sal farmaceuticamente aceptable del mismo y un inhibidor de acetilcolinesterasa para preparar un medicamento util para mejorar la cognicion. | |
| CO6270217A2 (es) | Formulaciones galenicas de alisquireno y valsartan | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| EP1781277A4 (en) | COMBINATION PREPARATION | |
| ATE540690T1 (de) | Insulinkombinationen | |
| AR056080A1 (es) | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine | |
| TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
| CL2007003318A1 (es) | Compuestos derivados de 4,5-difenil-pirrol-2-carboxamida; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento o la prevencion de enfermedades tales como sindrome de abstinencia a una sustancia, t | |
| CL2007002315A1 (es) | Compuestos derivados de piridina;composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades o trastornos que comprenden el dolor y/o sindrome del intestino irritable. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |